Immunomodulators in asthma therapy

Vesselin V. Dimov, Jeffrey R. Stokes, Thomas B. Casale

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

New developments in the field of allergy and immunology have yielded a variety of novel therapeutic approaches in recent years, and more agents are at the clinical trial stage. Among the therapeutic approaches discussed in this review are Toll-like receptor agonists, immunostimulatory oligodeoxynucleotides, orally and parenterally administered cytokine blockers, and specific cytokine receptor antagonists. Transcription factor modulators targeting syk kinase, peroxisome proliferator-activated receptor-γ, and nuclear factor-κB are also being evaluated in the treatment of asthma. The anti-IgE monoclonal antibody omalizumab has established effectiveness in patients with allergic asthma, but the criteria for selecting patients who are most likely to benefit from it are less clear. This review summarizes data from human clinical trials with immunomodulators to discuss the rationale for their use, their efficacy, and adverse events associated with them.

Original languageEnglish
Pages (from-to)475-483
Number of pages9
JournalCurrent Allergy and Asthma Reports
Volume9
Issue number6
DOIs
StatePublished - Oct 26 2009
Externally publishedYes

Fingerprint Dive into the research topics of 'Immunomodulators in asthma therapy'. Together they form a unique fingerprint.

  • Cite this